Merck today announced that it plans to move its U.S. Healthcare headquarters, currently located in Rockland, Mass., to Boston’s Seaport district.
The U.S. market is key to the company’s global Healthcare innovation strategy
New location will be a critical driver for future therapeutic launches and help support current portfolio
Merck, which operates its Healthcare business as EMD Serono in the U.S. and Canada, today announced that it plans to move its U.S. Healthcare headquarters, currently located in Rockland, Mass., to Boston’s Seaport district.
“The U.S. market is critical to our continued success as a global specialty innovator. Today we deliver important therapeutic options to more than 150,000 oncology, multiple sclerosis (MS) and fertility patients in the U.S.,” said Chris Round, President of EMD Serono. “This move serves as an important milestone in our journey to bring further innovation to address high unmet medical needs in areas where patients rely on us. Our vibrant new office setting in the Seaport district will bring EMD Serono into the center of the globally leading healthcare innovation hub to support our future growth.”
The company plans to introduce one new product or major indication every 1.5 years on average, beginning with two potential U.S. launches in 2025. EMD Serono remains committed to optimizing its impact across three therapeutic areas – in Neurology & Immunology, Oncology, and Fertility, which includes:
2 available oncology products across 5 indications in the U.S.
20+ years of expertise in MS
25+ years of leadership in Fertility
The U.S. Healthcare business plans to move to 200 Pier 4 Boulevard in Boston’s Seaport district in summer 2024. In addition to the Seaport site, the Healthcare business will maintain its global Research and Development hub in Billerica, Mass.
The company is currently designing the offices in keeping with the Merck global footprint of inclusive, accessible, and sustainable workplaces that foster collaboration and support a variety of hybrid working arrangements. The company is targeting LEED and WELL certifications in its design in alignment with Merck’s sustainability goals.
